Industry Standard Research (ISR) surveyed 114 individuals whose biopharmaceutical companies have been involved with at least one decentralized clinical trial (DCT) within the past year. Though not all respondents to our Decentralized Clinical Trials Market Outlook reported a smooth experience, nearly 60% came away with a positive overall impression of DCTs, while only 9% reported a negative impression. Even with some aspects regarded as challenging, respondents do not seem to consider decentralized trials as a temporary model. In fact, 80% of respondents expect the DCT model to be used more frequently than the traditional trial model over the next three years.
View Resource